Silence on Ranbaxy supply resumption a worry

India's drive towards compulsory licensing, increasing patent challenges and denial of patent protection to anti-cancer drug Glivec have not gone down well with multinational drug makers who are grumbling that India has become a difficult market for ...

In a landmark verdict, the Supreme Court last week dismissed Novartis plea for patent protection for cancer drug Glivec, ruling that the drug was not an innovation but a new form of a known drug. The decision can have wide-ranging implications for ...